Effects of Cannabis Use in Stage III-IV Non-small Cell Lung Cancer Patients
- Provision to sign and date the consent form
- Stated willingness to comply with all study procedures and be available for the duration of the study
- Have a diagnosis of stage III-IV non-small cell lung cancer (NSCLC) or other comparable tumor types
- Have intent to use Cannabis to treat their symptoms
- Report of other non-prescription drug use, such as cocaine, heroin, methamphetamine in the past 60 days
- Actively seeking or in treatment for any substance use disorder
- Acute illness other than cancer that could affect cognition or compliance per the decision of the study Doctor of Medicine (M.D.)
- Premenopausal females who are pregnant or trying to become pregnant. Participants who become pregnant while participating in the study will also no longer be eligible for participation
- A Telephone Interview for Cognitive Status (TICS) score indicating moderate or severe cognitive impairment at screening
I. To demonstrate the number of contacts necessary to enroll 30 eligible patients and demonstrate reasonable compliance with study procedures within six months of active recruiting.
Patients use their marijuana (cannabis) product of choice orally (PO) for 2 weeks then undergo blood collection and complete questionnaires, memory and thinking assessments at baseline then at 1 and 2 hours after each cannabis use.
After completion of study, patients are followed up at 1 month.
Trial Phase Phase NA
Trial Type Observational
University of Colorado Hospital
- Primary ID 18-0836
- Secondary IDs NCI-2020-01067
- Clinicaltrials.gov ID NCT03617692